Impact of a phone follow-up program on persistence with teriparatide or PTH(1-84) treatment.
A follow-up program to help patients suffering from severe osteoporosis during their therapy with teriparatide or PTH(1-84) has been designed and performed. The objective of this study was to evaluate the 18-month persistence on these therapies in patients participating in the program. We enrolled 382 patients who started teriparatide or PTH(1-84) following this program and compared them with a historical cohort of 398 patients treated with the same therapies but who did not participate in any follow-up program. At the beginning of the therapy, nurses trained patients on self-injection. Patients received one phone call per week during the first month, then one phone call per month and per 3 months during the following 5 and 12 months, respectively. In every call, nurses helped patients to resolve any possible issues and collected adverse event information. The persistence rate of the group following the program was 85.6%, 8.2% higher than that of the group not following any program (77.4%). The log-rank test on persistence rates on therapy in patients enrolled and not enrolled in the program was performed; the difference was statistically significant (P = 0.006). Discontinuation in the follow-up program group occurred mainly at early stages of the treatment due to adverse events. Our results show that patients suffering from severe osteoporosis treated with teriparatide or PTH(1-84) and enrolled in a follow-up program have higher persistence rates than patients not following the program.
Department of Medical and Surgical Disciplines, Section of Gerontology, University of Torino-Italy, AOU San Giovanni Battista, Torino, Italy. cristinatamone@alice.it
Cristina
C
Tamone
Gianfranco
G
Fonte
Anna
A
Panico
Pia Anna
PA
Molinatti
Patrizia
P
D'Amelio
Giovanni Carlo
GC
Isaia
D000368:Aged; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D010281:Parathyroid Hormone / Q000008:administration & dosage / Q000627:therapeutic use*; D013689:Telephone; D019379:Teriparatide / Q000008:administration & dosage / Q000627:therapeutic use*
D050071:Bone Density Conservation Agents; D010281:Parathyroid Hormone; D019379:Teriparatide